Advanced Lung Carcinoma: Clinical Trials

6 trials for Advanced Lung Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 terminated, 1 active not recruiting. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Recruiting 3, Terminated 2, Active not recruiting 1
Phase 22Recruiting 1, Terminated 1

Follow Advanced Lung Carcinoma: new trials by email Literature Review of Advanced Lung Carcinoma trials Research Report on Advanced Lung Carcinoma

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC
Phase 1RecruitingTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)6652025-03-312026-06-02
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
BBO-8520, Pembrolizumab, BBO-10203 - Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 1RecruitingTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)3502024-05-222026-09-03
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
silevertinib monotherapy - Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer
Phase 1 / Phase 2RecruitingBlack Diamond Therapeutics, Inc.2202022-03-312026-11-18
A Study to Investigate LYL797 in Adults With Solid Tumors
LYL797 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Phase 1TerminatedLyell Immunopharma, Inc.572022-03-292025-07-01
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy - Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center132021-03-292026-03-03
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Brigatinib, Local Consolidation Therapy - Advanced Lung Carcinoma, ALK Gene Rearrangement
Phase 1Active not recruitingM.D. Anderson Cancer Center352018-12-182026-11-10

Narrower conditions

Carcinoma, Non-Small-Cell Lung (5)  ·  Lung Neoplasms (5)  ·  Neoplasm Metastasis (3)  ·  Adrenal Gland Neoplasms (1)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Colorectal Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Liver Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Recurrence (1)  ·  Triple Negative Breast Neoplasms (1)

Broader conditions

Lung Diseases (6)  ·  Neoplasms (6)  ·  Neoplasms by Site (6)  ·  Respiratory Tract Diseases (6)  ·  Respiratory Tract Neoplasms (6)  ·  Thoracic Neoplasms (6)  ·  Bronchial Neoplasms (5)  ·  Carcinoma, Bronchogenic (5)  ·  Neoplastic Processes (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Carcinoma (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Endocrine Gland Neoplasms (2)

Interventions

pembrolizumab (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Carboplatin (1)  ·  Cetuximab (1)  ·  Cisplatin (1)  ·  Gemcitabine (1)  ·  Nivolumab (1)  ·  Pemetrexed (1)  ·  Radiosurgery (1)  ·  brigatinib (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (2)  ·  Black Diamond Therapeutics, Inc. (1)  ·  Lyell Immunopharma, Inc. (1)

Countries

United States (6)  ·  Australia (2)  ·  Canada (2)  ·  Denmark (1)  ·  Spain (1)

Top investigators

Jackie Walling, MBChB, PhD (1)  ·  James Welsh (1)  ·  Yasir Y Elamin, MD (1)

Results publications

PMID 41790032